Pull-and-Refiles Become Less Effective in Heading Off Second Requests on High-Profile Deals

Published on Sep 29, 2023

Pfizer (PFE), Seagen (SGEN) and other companies have found that a once tried-and-true procedural tactic to avoid an extended government investigation of their high-profile deals is proving less effective with the Biden administration. As the FTC in June approached the end of its initial 30-day review of Pfizer’s $43 billion bid to buy Seagen, a […]

Already have an account? Log in.

This article is currently locked and only available to subscribers. Request a trial to receive unlimited access to all articles.

View Only Unlocked Articles

© 2024 the Capitol Forum